title: Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
authors.forename: N
authors.initials: N
authors.lastname: Doser
authors.forename: P
authors.initials: P
authors.lastname: Sudre
authors.forename: A
authors.initials: A
authors.lastname: Telenti
authors.forename: V
authors.initials: V
authors.lastname: Wietlisbach
authors.forename: P
authors.initials: P
authors.lastname: Nicod
authors.forename: R
authors.initials: R
authors.lastname: Darioli
authors.forename: V
authors.initials: V
authors.lastname: Mooser
mesh_terms: D000328:Adult; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; C098320:efavirenz; D019438:Ritonavir